Case Study: Autolus Therapeutics achieves compliant, lower-cost manufacturing with Ignition by Inductive Automation

Autolus Therapeutics modernizes cancer therapy manufacturing with Inductive Automation in a 72,000-square-foot facility

Autolus Therapeutics, a London-based biopharmaceutical company developing next-generation T cell therapies for cancer, faced the challenge of modernizing its manufacturing facility. The company needed a new SCADA system capable of handling a wide variety of equipment communication protocols while also ensuring compliance with strict FDA and EU regulations. They selected the Ignition platform from Inductive Automation for its data acquisition, visualization, and alarming capabilities.

Inductive Automation's Ignition solution provided the necessary multilingual protocol support for Autolus's diverse equipment. It delivered strong compliance features for electronic records and signatures, and its unlimited licensing model significantly reduced costs. The implementation by system integrator Barry-Wehmiller Design Group resulted in a modernized process control system that offers improved mobility for operators and a solid foundation for a new manufacturing facility, aiding Autolus in its mission to deliver life-changing therapies.

Autolus Therapeutics